InVivoMAb anti-human CD220 / Insulin Receptor (Clone IR 83-22)
The IR 83-22 monoclonal antibody reacts with human CD220, also known as insulin receptor. CD220 is a type I transmembrane receptor tyrosine kinase which, upon binding to insulin, initiates several cellular effects, including glucose uptake, cell growth, differentiation, and apoptosis. These effects primarily occur in skeletal muscle, fat, and the liver. Neuronal CD220 signaling has been shown to have an important role in energy homeostasis, reproduction, and the development of neurodegenerative diseases. The IR 83-22 antibody has been shown to inhibit approximately 80% of insulin binding to IM-9 insulin receptor expressing cells.
This antibody is useful for:
Bio X Cell antibodies are specifically formulated for in vivo use and feature:
Ultra-low endotoxin levels
Preservative, stabilizer, and carrier protein-free
Recommended isotype control and dilution buffer:
InVivoMAb mouse IgG1 isotype control, unknown specificity
InVivoPure pH 7.0 Dilution Buffer
InVivoPure™ dilution buffers are specifically formulated and tested to satisfy the stringent requirements for in vivo applications. They are extremely low in endotoxin, have been screened for murine pathogens, tested in animal models for toxicity and are formulated with respect to buffer composition and pH to satisfy the requirements of Bio X Cell’s antibodies.